10 Things I Learned About SIBO That Explain Why It Keeps Coming Back

The more I study SIBO and work through people who have been dealing with it for years, the less I think the most important question is simply what will kill the bacteria.

Antibiotics such as rifaximin can be extremely useful. In methane-associated cases, other medications may be added. Herbal antimicrobials, elemental diets, dietary changes and other interventions can also reduce microbial burden and sometimes produce a dramatic improvement in bloating, bowel movements, food tolerance and other symptoms. The problem is that many people improve and then find themselves back in the same place several weeks or months later.

That is usually when the conversation shifts to motility. People learn about the migrating motor complex, motilin, serotonin, 5-HT4 receptors, acetylcholine, the vagus nerve, fasting between meals, ginger, erythromycin or prucalopride. Motility absolutely matters, but even that discussion can become too narrow because intestinal motility is not one pathway and the migrating motor complex is not a single switch that simply turns on and sweeps the small intestine clean.

For the small intestine to clear itself effectively, several things have to happen together. The bowel first has to sense that something is inside it. Sensory nerves have to detect stretch and chemical changes. The enteric nervous system has to process that information. Interstitial cells of Cajal and smooth muscle have to organize electrical activity into coordinated contractions. The segment behind intestinal contents has to contract while the segment in front relaxes. The muscle has to have enough energy to perform that work. Intestinal fluid has to move with the contraction. Mucus has to have the right physical properties. Bile and pancreatic secretions have to enter the lumen normally. The intestinal surface has to prevent excessive bacterial attachment, and eventually everything has to move through the terminal ileum and ileocecal region without excessive movement backward from the colon.

At the same time, the small intestine is constantly controlling microbial growth chemically and immunologically. Bile acids create pressure against certain organisms. Paneth cells release antimicrobial peptides. Secretory IgA helps keep bacteria away from the epithelial surface. The intestinal lining controls oxygen, fluid, electrolytes and nutrient availability. Immune cells communicate with the enteric nervous system, while the host also restricts access to metals and other nutrients that bacteria require for growth.

That means the small intestine is not simply a pipe that becomes too slow. It is a highly regulated environment that normally prevents large microbial communities from becoming established.

This is why I think the more useful question in recurrent SIBO is not only, “What bacteria do I have?” It is, “Why did my small intestine become an environment where those organisms could successfully remain and expand?”

That question becomes especially important when somebody had normal digestion for twenty, thirty or forty years before suddenly developing SIBO. The bacteria did not suddenly discover the small intestine. Something about the environment changed.

For one person that change may have followed food poisoning. For another it may involve diabetes, autonomic dysfunction, connective-tissue disease, altered bile physiology, pancreatic dysfunction, a medication that strongly slowed gastrointestinal transit, intestinal surgery, chronic inflammation, altered intestinal blood flow or several smaller changes occurring together.

Once the microbial population expands, the problem can become even more complicated because the microorganisms themselves begin changing the environment. They modify bile acids, produce methane and hydrogen sulfide, release inflammatory products, interact with nutrient-sensing pathways, consume each other’s metabolites and potentially form structured communities that become harder to remove. The original physiological problem may allow SIBO to develop, and the resulting microbial ecosystem may then make recovery more difficult.

That is one reason why killing the organisms and restoring the physiology that normally controls them are not always the same thing.

1. Food poisoning can change intestinal function long after the infection itself is gone

Some of the clearest SIBO stories begin after an episode of food poisoning. A person develops severe gastroenteritis, eventually recovers from the acute infection, but their gastrointestinal function never completely returns to what it was before. Bloating appears, bowel movements change, food becomes more difficult to tolerate, and months later they may be dealing with recurrent SIBO.

One mechanism that may help explain this involves cytolethal distending toxin B, usually abbreviated CdtB. Several organisms associated with gastrointestinal infections can produce this toxin. The immune system recognizes CdtB as foreign and produces antibodies against it.

The interesting part is that portions of CdtB can resemble vinculin, a protein that belongs to our own cells and participates in cellular structure and adhesion. This creates the possibility of molecular mimicry, where an immune response that originally developed against a bacterial protein may also react with a structurally similar human protein.

Why would that matter for SIBO? Because intestinal motility depends on much more than the muscle being able to contract. It depends on an organized network of enteric neurons, interstitial cells of Cajal, smooth muscle and supporting structures that coordinate where a contraction begins, how far it travels and whether the bowel ahead of the contraction relaxes properly.

A disturbance in that system does not have to produce complete intestinal paralysis. The person can still digest food, have bowel movements and feel their intestine moving. What may change is the efficiency of clearance between meals.

That difference is extremely important for bacteria. A microorganism that enters the small intestine and is quickly pushed downstream has limited time to establish itself. Give that same organism several additional hours of residence time, repeatedly, and it has a much greater opportunity to divide, interact with other organisms and become part of a stable microbial community.

This is also why two people can experience apparently similar food poisoning and have completely different long-term outcomes. One person returns to normal within days. Another develops years of altered bowel function. The difference may not be the infection alone, but how the person’s immune and enteric nervous systems responded to it.

So when someone tells me their SIBO began after food poisoning, I am not only interested in which organism caused the original illness. I am interested in whether that event left behind a change in the physiological systems responsible for clearing the small intestine.

The infection may have lasted a week. The physiological consequence may last much longer.

2. Having intestinal contractions does not necessarily mean the intestine is clearing itself properly

One of the most important distinctions in SIBO is the difference between movement and effective forward movement.

The intestine can contract frequently without moving its contents efficiently toward the colon. That is because normal propulsion requires several events to happen in the correct order.

The bowel behind intestinal contents has to contract while the bowel ahead relaxes. If both areas contract at the same time, the contents can become trapped between them. If contractions occur but do not travel very far, material can be mixed in place rather than moved forward. If the intestine produces strong segmentation but poor propulsion, it can look very active while bacterial residence time remains long.

Interstitial cells of Cajal are important in this process because they participate in organizing electrical activity through the intestinal muscular wall. They interact with smooth muscle and enteric neurons and help turn individual electrical signals into coordinated patterns of movement.

If these networks become disrupted by inflammation, diabetes, oxidative stress, ischemia, aging, connective-tissue disease or a post-infectious process, the intestine may still contract but lose some of its ability to coordinate those contractions.

The balance between excitatory and inhibitory signaling is equally important. Acetylcholine helps generate smooth-muscle contraction, but propulsion also requires relaxation in the segment ahead. Nitric oxide released from inhibitory enteric neurons is one of the signals involved in that relaxation.

This means increasing contraction is not always the same as improving clearance. If the problem is poor coordination between contraction and relaxation, increasing excitatory drive can create more pressure without producing much additional forward movement.

The sensory system matters too. The intestine first has to detect that it is being stretched or filled before it can generate the correct reflex response. Intrinsic sensory neurons, visceral C-fibers and mechanosensitive channels such as Piezo1 and Piezo2 participate in detecting stretch and changes in the intestinal environment.

This is one reason small-fiber neuropathy, autonomic neuropathy and some post-infectious neurological conditions are interesting in complicated SIBO cases. C-fibers are usually discussed in relation to pain and visceral sensitivity, but sensory nerves also participate in gastrointestinal reflexes involving motility, secretion and blood flow.

Connective tissue can affect the same process because mechanosensitive channels only work if mechanical force reaches them properly. If the surrounding tissue is excessively compliant, as can occur in some hypermobility phenotypes, stretch may be transmitted differently. If the tissue becomes excessively stiff or fibrotic, as in systemic sclerosis, the mechanics change in another direction.

This gives us a form of dysmotility where the smooth muscle itself may not be the primary problem. The nervous system and muscle may still exist, but the system that detects stretch and converts it into coordinated movement may not be working normally.

That is why I do not think every person who fails a prokinetic simply needs a stronger one. A medication acting on serotonin, dopamine or motilin may increase one signal, but the limiting step may be electrical coordination, sensory input, smooth-muscle function, downstream relaxation or the mechanics of the tissue itself.

For bacteria, what matters is not how much the intestine moves. What matters is whether that movement actually removes them.

3. Motility can only clear bacteria if the fluid and mucus inside the intestine allow them to be moved

The physical environment inside the intestine is another part of SIBO that I think receives far too little attention.

Imagine trying to rinse bacteria out of two tubes. One contains thin fluid where the organisms are freely suspended. The other contains thick mucus with bacteria attached to the wall inside a sticky biological matrix.

The same amount of muscular pressure will not clean those two tubes equally well.

CFTR provides a useful example. This chloride channel helps control chloride and bicarbonate secretion, which affects water movement, intestinal pH and mucus properties. In cystic fibrosis, where CFTR function is severely impaired, gastrointestinal secretions become thicker and bacterial overgrowth is common.

The broader lesson is that intestinal washout depends on both muscle contraction and the physical properties of the material that contraction is trying to move.

Bacteria can also change those physical properties themselves.

When bacterial numbers remain low, many organisms are floating freely in intestinal fluid. As local density rises, bacteria begin detecting chemical signals produced by neighboring organisms. These quorum-sensing systems can change bacterial gene expression and promote the production of extracellular polysaccharides, proteins and DNA.

The bacteria can then become embedded inside a structured matrix known as a biofilm.

A biofilm behaves very differently from individual bacterial cells. Instead of hundreds or thousands of separate organisms floating through intestinal fluid, you now have a community physically attached to mucus or the intestinal surface.

Fluid mechanics becomes important here because fluid near a fixed surface moves much more slowly than fluid farther away from that surface. A bacterial community close to the intestinal wall therefore experiences less mechanical shear than organisms suspended in the center of the lumen.

This creates a possible progression in chronic SIBO. Initially, slower clearance gives bacteria more time to remain in the small intestine. Longer residence time increases the opportunity for organisms to attach to mucus or the mucosal surface. Once more structured communities develop, the intestine now has a harder physical problem to solve.

The epithelial surface itself can influence attachment. The brush border is covered by a glycocalyx rich in electrically charged molecules, and enterocytes continuously use energy to maintain ion gradients across the intestinal wall. Bacterial surfaces also carry electrical charge.

Changes in epithelial energy metabolism, ion transport, mucus composition or bacterial degradation of the glycocalyx may therefore influence how easily organisms come into contact with and remain attached to the epithelial surface.

This is why simply restoring the migrating motor complex may not always immediately restore normal microbial clearance in longstanding disease. The system may no longer be trying to move freely suspended bacteria. It may be trying to remove organisms that have become physically integrated into mucus and surface-associated communities.

4. The intestinal lining helps decide which bacteria are able to dominate

The intestinal microbiome does not exist independently of the tissue surrounding it. The intestinal epithelium continuously creates the chemical environment in which microorganisms have to compete.

One particularly important variable is oxygen and redox chemistry.

Different bacteria obtain energy in very different ways. Some rely heavily on fermentation. Others, including many members of Enterobacteriaceae such as E. coli and Klebsiella, can use oxygen or alternative electron acceptors such as nitrate when they become available.

That can give them an important growth advantage.

Enterocytes are metabolically demanding cells. They absorb nutrients, move ions and maintain the intestinal barrier, all of which requires ATP and oxygen. Inflammation, mitochondrial dysfunction or altered blood flow can change how these cells use oxygen.

Inflammation can also increase nitric oxide and reactive oxygen chemistry, creating compounds such as nitrate that certain bacteria are able to use for respiration.

The result is that an organism already present at low abundance can suddenly find itself in a much more favorable metabolic environment.

This is very different from the idea that dysbiosis always means a new bad bacterium arrived from somewhere else. Sometimes the host environment may simply begin rewarding an organism that was already present.

The intestinal villus adds another interesting layer. The blood vessels inside each villus have a counter-current arrangement where arterial and venous blood run close together. Some oxygen can move between these vessels before reaching the very tip of the villus, which makes the villus tip relatively sensitive to reductions in blood flow.

If splanchnic circulation becomes abnormal, the absorptive cells at the villus tip may have less energy available for nutrient transport.

Now carbohydrates and other nutrients that would normally be rapidly absorbed can remain in the intestinal lumen for longer periods.

Microorganisms gain additional substrate at the same time that the epithelial redox environment is changing.

This may be particularly relevant in some autonomic conditions where gastrointestinal blood-flow regulation is abnormal.

The immune system can also change microbial competition through something called nutritional immunity. During inflammation, proteins such as calprotectin bind metals including zinc and manganese. The purpose is to deprive microbes of nutrients they need for growth.

The problem is that different organisms have different abilities to compete under these conditions.

Some Enterobacteriaceae possess very high-affinity metal transport systems, including pathways such as ZnuABC, that allow them to acquire zinc even when the host is aggressively restricting it. They can therefore continue growing while more vulnerable organisms slow down.

The host is trying to suppress microbial growth, but the resulting environment can act as a selection pressure favoring organisms best equipped to survive it.

This is why simply identifying Klebsiella or E. coli is not enough for me. I want to know what changed in the intestinal environment that made those organisms more competitive.

5. Bile acids help control the small-intestinal microbiome, and bacteria can alter that system

Bile is usually discussed as something the liver makes to help digest fat. In SIBO, I think that explanation leaves out much of the important biology.

Bile acids interact directly with microorganisms and create chemical pressure that helps shape which organisms can survive in the small intestine. They also act as signaling molecules through receptors such as FXR and TGR5.

The microbial community then modifies those same bile acids.

Many bacteria produce bile salt hydrolase enzymes that remove the conjugated amino acid from bile acids. Other bacterial enzymes transform them further.

If excessive microbial biomass develops in the proximal or middle small intestine, those transformations start happening earlier and more extensively than they normally would.

Now the bile acid pool reaching the distal intestine is different from the one originally released into the small bowel.

That can affect fat absorption, antimicrobial pressure and signaling through bile acid receptors.

FXR is particularly interesting because ileal FXR signaling participates in the FGF19 pathway that tells the liver how much bile acid to produce. Bacteria can therefore modify the molecules that help regulate the host’s own bile acid system.

This creates the possibility of a feedback loop. Reduced bile delivery, abnormal gallbladder function, ileal dysfunction or disturbed enterohepatic circulation may make the small intestine more permissive to microbial expansion. Once bacteria expand, they change bile acids further. Those altered bile acids then affect the host again.

This is also a good example of why SIBO susceptibility is probably determined by combinations of vulnerabilities rather than a single defect.

Two people may have equally slow intestinal transit. One has strong bile delivery, normal pancreatic function and intact mucosal immunity. The other has the same degree of delayed transit but weaker bile pressure and impaired mucosal defense.

The second person may develop SIBO much more easily because they have less physiological reserve.

6. Pancreatic function and Paneth-cell immunity can determine how much microbial growth the intestine can tolerate

Pancreatic insufficiency is often explained by saying that poorly digested food gives bacteria more substrate.

That is true, but pancreatic secretions also shape the entire chemical environment of the proximal small intestine.

Bicarbonate controls luminal pH. Proteases digest proteins. Lipase changes how fats are processed. When pancreatic output falls, the amount and form of nutrients reaching the more distal intestine changes, as does the chemical interaction between pancreatic secretions, bile and the intestinal surface.

The mucosa also has another defense system that operates independently of motility.

Paneth cells sit at the base of the intestinal crypts and produce antimicrobial molecules including defensins and lysozyme. These substances help protect the crypt environment and limit bacterial contact with the stem cells that constantly regenerate the intestinal lining.

Paneth cells manufacture enormous amounts of proteins, which means they depend heavily on intracellular protein-folding and recycling systems.

Autophagy is one of those systems.

Pathways involving genes such as ATG16L1 and NOD2 help Paneth cells maintain their antimicrobial granules. If autophagy becomes impaired or endoplasmic-reticulum stress becomes excessive, the cells may remain present but lose some of their ability to manufacture and release antimicrobial proteins.

That means somebody could theoretically have relatively normal intestinal transit but weaker antimicrobial protection at the mucosal surface.

Secretory IgA adds another layer. IgA can coat microorganisms and reduce their ability to attach directly to the epithelium.

This matters because the amount of motility impairment required to produce SIBO may depend on how well all these other systems are working.

One person can tolerate somewhat slower transit because bile, Paneth-cell function, IgA and epithelial defenses remain strong. Another person with weaker mucosal defenses may develop overgrowth with a much smaller motility abnormality.

Circadian biology may influence these defenses as well. Intestinal epithelial cells contain clock genes such as BMAL1 and CLOCK that regulate metabolic and immune functions throughout the day. Antimicrobial activity is therefore not necessarily identical at every hour.

This gives another reason why meal timing and fasting periods may matter beyond simply “allowing the MMC to happen.” The timing of food intake also interacts with the biological timing of intestinal metabolism and immune defense.

7. The immune system and the enteric nervous system are physically maintaining each other

The enteric nervous system does not operate separately from the immune system.

Macrophages live within the muscular layer of the intestine directly beside enteric neurons. These muscularis macrophages participate in maintaining normal neuronal function.

One part of that relationship involves BMP2, a signaling molecule produced by macrophages that can act on neighboring enteric neurons. The neurons also send signals back to the macrophages.

This means normal intestinal motility partly depends on an ongoing conversation between immune cells and nerves.

That becomes important in chronic inflammation.

Inflammation does not only create temporary diarrhea, pain or swelling. Persistent changes in immune signaling can potentially alter the environment supporting the neurons responsible for intestinal coordination.

Enteric glial cells add another layer. These cells surround enteric neurons and help regulate their environment. They also respond strongly to extracellular ATP and other danger signals.

ATP is interesting because its meaning depends on where it is.

Inside the cell, ATP is energy.

Outside the cell, ATP can act as an alarm signal.

Rapid bacterial growth, bacterial death and injured intestinal cells can all increase extracellular ATP. Purinergic receptors such as P2X7 can detect that ATP and promote inflammatory signaling involving enteric glia and immune cells.

Intestinal alkaline phosphatase, or IAP, normally helps break down extracellular nucleotides and also detoxifies components of bacterial LPS.

If IAP activity falls while microbial biomass increases, extracellular ATP and bacterial inflammatory products may have a greater effect on the enteric environment.

Now imagine how this can become self-reinforcing. An upstream motility problem allows bacterial numbers to rise. Greater microbial burden increases LPS, extracellular ATP and other inflammatory signals. Enteric glia and immune cells become more reactive. Neuronal coordination becomes less efficient. Motility deteriorates further, which allows even more bacteria to remain.

At that point, it becomes very difficult to say that SIBO is simply caused by dysmotility because the overgrowth itself may now be contributing to the dysmotility.

8. Microbial metabolites may activate the same hormonal braking systems that normally slow digestion after a large meal

The intestine has built-in systems for sensing nutrients.

When nutrients reach the distal intestine, enteroendocrine cells release hormones including GLP-1 and peptide YY. These hormones help slow gastric emptying and upper gastrointestinal transit so the distal bowel has time to process what has already arrived.

This is part of what is called the ileal brake.

The interesting part is that bacteria also produce molecules capable of interacting with nutrient-sensing pathways.

Microbial fermentation generates short-chain fatty acids. Bacteria also produce indoles and modify bile acids. Enteroendocrine cells contain receptors such as FFAR2, FFAR3 and other chemical sensors capable of responding to this environment.

If a large microbial population begins producing those signals earlier in the gastrointestinal tract than usual, it could influence the same hormonal systems that normally regulate the speed of digestion.

That creates another possible feedback loop. More microbial metabolism generates more signaling molecules. Those signals increase inhibitory feedback on gastrointestinal transit. Slower transit gives microorganisms more time to metabolize incoming nutrients.

This does not mean the bacteria are deliberately trying to slow the host. It simply means the receptor cannot distinguish why a molecule is present. If the correct ligand reaches it, it responds.

This is one reason GLP-1 physiology is relevant to SIBO discussions. GLP-1 receptor agonist medications demonstrate very clearly how powerfully this endocrine system can alter gastric and intestinal transit.

Other hormonal systems also influence gastrointestinal physiology, including motilin, ghrelin, CCK, somatostatin, thyroid hormone and the GH-IGF-1 axis.

The GH-IGF-1 system is especially interesting because it supports tissue growth, intestinal adaptation and smooth-muscle biology, although I would not interpret low IGF-1 as a simple cause of SIBO.

The larger point is that gastrointestinal movement is being regulated by neural, mechanical, endocrine and microbial signals simultaneously.

That is why there may not be one perfect prokinetic capable of overriding every kind of upstream dysfunction.

9. Methane represents a microbial partnership, not simply a positive breath-test number

Methane is one of the best examples of why microbial ecosystems have to be understood as communities rather than lists of organisms.

Methanogens such as Methanobrevibacter smithii are not bacteria. They belong to another domain of life called archaea.

They survive by consuming hydrogen produced by other microorganisms.

Many bacteria generate hydrogen when they ferment carbohydrates. If hydrogen accumulates around those bacteria, some fermentation reactions become progressively less energetically favorable.

Methanogens solve that problem by consuming the hydrogen and combining it with carbon dioxide to produce methane.

That does something important for the bacteria producing the hydrogen.

By continuously removing one of their metabolic waste products, the methanogens make continued fermentation easier.

This relationship is called interspecies hydrogen transfer.

It means one microorganism’s waste becomes another microorganism’s fuel, while the second organism improves the metabolic environment for the first.

This is why looking only at abundance can miss how important a microorganism is. A species present in relatively modest numbers can have a large ecological effect if it controls a metabolite that many other organisms depend on.

Methane is also associated with slower intestinal transit.

This creates another potentially self-reinforcing relationship. Slower transit gives methanogens more time to establish themselves. Increased methane production is associated with slower transit, which provides even more time for the community to persist.

That is why intestinal methanogen overgrowth is biologically different from simply having a high hydrogen breath test.

It represents a different metabolic network.

And it shows why treating one organism without considering the organisms supplying its substrate may sometimes produce incomplete results.

10. Chronic SIBO may eventually become an ecosystem that helps maintain itself

This is where all of these mechanisms begin to connect.

SIBO may initially begin with one major vulnerability. Food poisoning changes enteric physiology. Diabetes damages neural coordination. Pancreatic output declines. Bile physiology changes. A medication slows intestinal transit. Connective tissue alters mechanosensation. Splanchnic circulation changes. The ileocecal region becomes less effective at preventing backward movement.

That first defect creates an opportunity.

Microbial residence time increases or antimicrobial pressure falls, and bacterial numbers begin rising.

Once those organisms become established, however, they start changing the environment themselves.

Methanogens consume hydrogen and produce methane. Sulfur-metabolizing organisms generate hydrogen sulfide. Bacteria alter bile acids, modify mucus, release LPS and extracellular ATP, interact with nutrient-sensing receptors and potentially develop structured biofilms.

Hydrogen sulfide is particularly interesting because concentration changes its biological effect. At low concentrations H2S acts as a normal signaling molecule. At sufficiently high concentrations, it can inhibit cytochrome c oxidase, also known as Complex IV, one of the final enzymes of the mitochondrial respiratory chain.

Smooth muscle, enteric neurons and intestinal epithelial cells all depend on mitochondrial ATP production.

If local H2S exposure becomes sufficiently high to interfere with mitochondrial respiration, microbial metabolism could theoretically make the host tissue responsible for clearing those organisms function less efficiently.

Inflammation then adds another layer by changing oxygen, nitrate, zinc and other components of the intestinal environment. Those changes may favor microbial populations specifically adapted to inflammatory conditions.

The ileocecal region can continuously contribute organisms as well. The colon contains far greater microbial biomass than the proximal small intestine, so changes in pressure, anatomy or retrograde motor activity can increase movement of colonic organisms back toward the ileum.

Other regulatory layers are only beginning to be understood. Intestinal epithelial cells release extracellular vesicles containing microRNAs that may influence bacterial gene expression. Bacteriophages infect specific bacterial populations and help shape microbial competition. Circadian rhythms change intestinal immune and metabolic activity across the day.

This is why longstanding recurrent SIBO may not behave like the same biological problem that originally started it.

The first event may have been impaired motility.

Years later the person may also have abnormal bile acid metabolism, altered epithelial signaling, methane cross-feeding, inflammation and mucosal microbial communities that are more difficult to remove.

Treating the microbial biomass can still be extremely valuable. Sometimes reducing that burden gives the intestinal system enough room to recover.

But microbial reduction and restoration of colonization resistance are not necessarily the same thing.

That distinction may explain why one person takes rifaximin once and never develops SIBO again while another person improves for several months and then relapses repeatedly.

Both had SIBO.

They may not have had the same disease process underneath it.

This is why I think the timeline becomes so important in recurrent cases. I want to know what happened before the first episode. Did the problem begin after food poisoning? Did constipation appear first? Did autonomic symptoms begin before gastrointestinal symptoms? Was there pancreatic or gallbladder disease? Was the person taking a medication that profoundly changed gastrointestinal transit? Did the onset occur after surgery? Was there a major infection? Did the person always have slow transit, or did something suddenly change?

I also want to know what antimicrobial treatment actually changed.

If rifaximin eliminates bloating but the person remains severely constipated, that tells us something. If the breath test becomes negative but food tolerance remains abnormal, that tells us something different. If symptoms disappear completely and remain gone after a single course, the underlying colonization resistance may have recovered. If symptoms return predictably every few months, I become much more interested in what is recreating the same ecological conditions.

The small intestine normally invests an enormous amount of biological energy in preventing bacterial overgrowth. It moves organisms downstream, limits their ability to attach, exposes them to bile and antimicrobial molecules, controls nutrient availability, maintains epithelial metabolism and coordinates immune, neural, endocrine and mechanical systems across several meters of bowel.

Persistent SIBO means something in that system has changed.

Sometimes there is one obvious upstream defect. Sometimes several smaller weaknesses have accumulated until the intestine no longer has enough reserve to keep microbial growth under control. And in longstanding cases, the microbial community that develops afterward may become part of the reason the original physiology does not easily return.

That is why I do not think antibiotics, antimicrobials, prokinetics or dietary strategies should be dismissed. They can all be useful and sometimes necessary.

The more important question is what each intervention is actually treating.

Reducing bacterial biomass treats the overgrowth. Improving motility can improve washout. Supporting bile or pancreatic physiology changes luminal chemistry. Addressing an underlying neurological, immune, vascular or structural problem may change why the overgrowth was able to develop in the first place.

For recurrent SIBO, those are different layers of the same problem.

And that is why simply asking what will kill the bacteria is often not enough.